Loading patent…
AssigneeMTM Laboratories, AG
InventorsRuediger Ridder, Anja Reichert, Magnus Von Knebel Doeberitz, Matthias Herkert, Alexander Duwe, Rainer Hipfel, Peter Martin
Estimating the term…
The present invention relates to a method for the early diagnosis of neoplastic disorders such as cancers as well as their precursor stages, particularly cancers of the respiratory tract, the urinary system, the reproductive tract, cancer associated with HPV infection or cancer of the anogenital tract, from solubilized body samples. The invention is also directed to test kits usable for this purpose as well as in-vitro diagnostic devices. The development of the kits and in-vitro diagnostic devices for the above purpose is also one aspect of the present invention.
A method for detecting neoplastic disorders from a solubilized body sample of a human subject, the method comprises the steps of:
An in-vitro diagnostic device comprising only probes of one specificity fixed to a solid phase, wherein the probes of the one specificity are specific for a marker molecule selected from the group consisting of i) a cyclin dependent kinase inhibitor selected from the group consisting of p16INK4a, p13.5, p14, p15INK4b, p18INK4c, p19INK4d, p21WAF1/CIP1, and p27KIP1;
An in-vitro diagnostic device comprising a probe, selected from the group consisting of an antibody, an antibody fragment, a miniantibody, or a peptidomimetic comprising an antigen binding epitope, and a nucleic acid specific for a marker molecule selected from the group consisting of i) a cyclin dependent kinase inhibitor selected from the group consisting of p16INK4a, p13.5, p14, p15INK4b, p18INK4c, p19INK4d, p21WAF1/CIP1, and p27KIP11;
A hybrid capture device being a research device or an in-vitro diagnostic device comprising nucleic acids complementary or reverse complementary to one or more cyclin-dependent kinase inhibitor nucleic acids, wherein the cyclin-dependent kinase inhibitor is selected from the group consisting of p16INK4a, p13.5, p14, p15INK4b, p18INK4c, p19INK4d, p21WAF1/CIP1, p27KIP1 and p14ARF for detection of overexpression of said one or more cyclin-dependent kinase inhibitors in a solubilized body sample.
29-41. (canceled)
A method for assessing diagnosis of medically relevant conditions from a solubilized LBC sample comprising
58-84. (canceled)
Dependencies are inferred from the claim text.